Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 154

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 154
---
 operation of the SEC’s Public Reference Room by calling the SEC in the U. S. at 1-800-SEC-0330.
The SEC also maintains a website at www. sec. gov that contains reports, proxy statements and other information regarding registrants that
file electronically with the SEC. Our annual reports and some of the other information we submitted to the SEC may be accessed through
this website. In addition, material we filed can be inspected on the Canadian Securities Administrators’ electronic filing system,
SEDAR+, accessible at the website www. sedarplus. ca. This material includes our Management Information Circular for our annual meeting
of shareholders to be held in 2024 to be furnished to the SEC on Form 6-K, which provides information including directors’ and
officers’ remuneration and indebtedness and principal holders of securities. Additional financial information is provided in our
audited annual financial statements for the year ended December 31, 2024 and our MD& A relating to these statements included elsewhere
in this Annual Report on Form 20-F. These documents are also accessible on SEDAR+ (www. sedarplus. ca) and on EDGAR (www. sec. gov).

  Subsidiary   
  information  
 ───────────────

Not
required.

  Item      Quantitative                                   
  11.       and Qualitative Disclosures About Market Risk  
 ───────────────────────────────────────────────────────────

Fair
value

The
Company classifies its financial instruments in the following categories: “ Financial assets at amortized cost”; “ Financial
liabilities at amortized cost”; and “ Fair value through the profit or loss”.

  The                                                                                                                                  
  Financial                                                                                                                            

The
carrying values of all of the aforementioned financial instruments approximate their fair values due to their short-term maturity or
to the prevailing interest rates of these instruments which are comparable to those of the market.

The
Black-Scholes valuation methodology uses inputs in calculating fair value, as defined in IFRS 13, which establishes a hierarchy that
prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets
for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).

Financial
risk factors

The
following provides disclosures relating to the nature and extent of the Company’s exposure to risks arising from financial instruments,
including credit risk, liquidity risk